Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2020

View Archived Issues

Copper escort alleviates Menkes disease

Immunity-related pathways contribute to the genetic burden of asthma pathology, new GWAS shows

Phase I data presented for LC51-0255

TBR-760 results in complete arrested tumor growth in mouse model of NFPA

Discovery of potent BACE1 inhibitor, AM-6494

First patient dosed in phase I/II study of TJD5 in China

Sunovion discontinues development of dasotraline

New androgen receptor antagonists described by ESSA Pharma

Enrollment of first patient in phase III study of viltolarsen in boys with DMD

Insilico Medicine Hong Kong discovers DDR1 inhibitors

Ascletis receives IND approval in China for clinical development of ASC-41 in NASH

Nurix Therapeutics patents Bruton tyrosine kinase-degrading compounds

ViiV Healthcare discovers new HIV-1 Capsid protein p24 assembly inhibitors

New adenosine A2A and A2B receptors disclosed by Merck KGaA

miRNA-126-5p circulating levels are decreased in severe sepsis

Improved therapeutic index could reduce opioid toxicity

Blueprint Medicines' BLU-847 shows activity against wild-type and mutant tyrosine kinase receptors

Immunic receives approval to begin phase II study of IMU-838 for COVID-19

SHISA4 expression proven useful to monitor nintedanib therapy in patients with IPF

Merck & Co. reports phase II data on MK-6482 for VHL disease-associated ccRCC

Vyriad opens phase II trial of Voyager-V1 in combination with cemiplimab for cancer

Viela reports interim phase Ib data on VIB-7734 in cutaneous lupus erythematosus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...